All In Biotech

Drug Trial Radar · NCT03334617

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).

Last checked: Nov 19, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

528

Actual

Start

Dec 18, 2017

Primary completion

Sep 13, 2024

Study completion Sep 11, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • DurvalumabDrug

    Participants will receive IV infusion of durvalumab as stated in arm description.

  • DanvatirsenDrug

    Participants will receive IV infusion of danvatirsen as stated in arm description.

  • CeralasertibDrug

    Participants will receive oral tablet of ceralasertib as stated in arm description.

  • VistusertibDrug

    Participants will receive oral tablets of vistusertib as stated in arm description.

  • OlaparibDrug

    Participants will receive oral tablets of olaparib as stated in arm description.

  • OleclumabDrug

    Participants will receive IV infusion of oleclumab as stated in arm description.

  • Trastuzumab deruxtecanDrug

    Participants will receive IV infusion of trastuzumab deruxtecan as stated in arm description.

  • CediranibDrug

    Participants will receive oral tablets of cediranib as stated in arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)Time frame: Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)

Locations

45 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California

  • Research Site

    Fullerton, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Angeles, California

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Chicago, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    St Louis, Missouri

  • Research Site

    New York, New York

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Innsbruck, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Brampton, Ontario, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Bordeaux, France

  • Research Site

    Nantes, France

  • Research Site

    Paris, France

  • Research Site

    Villejuif, France

  • Research Site

    Berlin, Germany

  • Research Site

    Esslingen a.N., Germany

  • Research Site

    Großhansdorf, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Haifa, Israel

  • Research Site

    Kfar Saba, Israel

  • Research Site

    Petah Tikva, Israel

  • Research Site

    Ramat Gan, Israel

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.